DuPont
DD · What the business does, what can go wrong, and how options sellers approach it
What it does
DuPont de Nemours is a specialty materials and chemicals company. It makes engineered products and technologies that other manufacturers use inside their own goods. Its customers span water treatment, healthcare and medical devices, construction, industrial manufacturing, and transportation.
The company has reshaped its portfolio through mergers, spinoffs and divestitures, so the exact mix of businesses changes over time.
How it makes money
DuPont sells materials, components and formulations, usually under ongoing supply relationships. Its products are often specified into a customer's design, such as a water filtration membrane, a building insulation system, or a material used in a medical product. That can make customers slow to switch.
Profit depends on pricing, the cost of raw materials and energy, and how fully its plants are used.
Why investors own it
- Exposure to long-term themes such as water scarcity, healthcare demand and efficient buildings.
- A focus on specialty products, which tend to carry better margins than basic commodity chemicals.
- A history of reshaping its portfolio, which some investors view as a way to sharpen focus.
- Cash returned to shareholders through dividends and buybacks, though neither is guaranteed.
What can go wrong
- Demand in construction, industrial and auto markets rises and falls with the economic cycle.
- Raw material, energy and currency swings can squeeze margins.
- Restructuring and divestitures can disappoint, distract management, or leave a smaller, less diversified company.
- Environmental and legal liabilities tied to chemical manufacturing and past products can be costly and slow to resolve.
- Competition from large chemical makers and lower-cost producers can pressure pricing.
What to watch
- Organic sales growth and volume versus price trends
- Operating EBITDA margin and free cash flow
- Management guidance changes
- Portfolio announcements, such as spinoffs or sales
- Environmental and legal developments
Options income angle
Options on DD are generally reasonably liquid, though thinner than in mega-cap names, and spreads can widen on less active strikes.
Implied volatility tends to rise around earnings, guidance changes, and news about the company's structure.
One caution for premium sellers: deal or separation news can cause price gaps that outrun the premium collected, and any covered call caps the upside above its strike if shares rally sharply.
What the latest 10-K says
A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended December 31, 2025, filed February 17, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The filing in brief
DuPont finished a year of major reshaping: it spun off its electronics business as Qnity on November 1, 2025, and agreed to sell its Aramids business. The remaining company reported net sales of $6,849 million, with Healthcare & Water Technologies growing and Diversified Industrials shrinking. The filing also shows how many tax and legacy chemical (PFAS) liabilities from past separations still sit with DuPont.
How the business did
- Net sales rose to $6,849 million from $6,719 million, helped by higher volume and offset by lower local price and product mix. Pre-tax income from continuing operations was $200 million, versus $117 million in 2024, and the effective tax rate was 51.0 percent.
- Healthcare & Water Technologies had net sales of $3,233 million, up 9 percent, led by medical packaging, biopharma and water markets. Its Operating EBITDA (a profit measure that adds back interest, depreciation and amortization, with other adjustments) was $972 million, up 15 percent.
- Diversified Industrials had net sales of $3,616 million, down 3 percent, on weak construction markets. Its Operating EBITDA was $800 million, down 5 percent.
- Cash provided by operating activities of continuing operations was $560 million, down from $765 million, mainly from swap settlements, debt-exchange fees and working capital. Total debt fell to $3.2 billion from $7.2 billion. Dividends paid were $597 million, and a $500 million accelerated share repurchase (ASR) was completed in January 2026.
- Unusual items: a $768 million goodwill impairment on Aramids (reported in discontinued operations, meaning businesses sold or spun off), a $73 million charge on an abandoned consolidation system, and $203 million of acquisition, integration and separation costs.
Risks specific to this company
- The Qnity spin-off must qualify as tax-free. If the IRS disagrees, DuPont could owe significant taxes, with some shared with Qnity at 56 percent DuPont and 44 percent Qnity.
- DuPont remains liable for legacy obligations from the Dow and Corteva separations, including joint liability for certain prior-period taxes and indemnities that may not fully cover PFAS-related stray liabilities.
- PFAS cost-sharing under a 2021 agreement with Corteva and Chemours depends on litigation and regulation. A proposed New Jersey settlement led to a $186 million pre-tax charge in 2025 and is payable over 25 year, pending a final court order.
- The Aramids sale is expected to close around the end of the first quarter 2026 but needs regulatory approvals. DuPont would receive pre-tax cash proceeds of approximately $1.2 billion, a $300 million note and an equity stake.
- China and Hong Kong were approximately 10 percent of net sales, and international operations were approximately 53 percent. China's market regulator opened an antitrust investigation of the Tyvek business, since suspended; Tyvek sales to China were approximately 1 percent of net sales.
- The company must keep an investment-grade credit rating to hold down borrowing costs. A Corteva letter agreement also resets DuPont's Minimum EBITDA at $1.4 billion, limiting how it can divest businesses without passing along indemnities.
What management is watching
- For 2026, management expects continued growth in Healthcare and Water, Building Technologies about flat, and low-single digit growth in Industrial Technologies on aerospace and recovering markets.
- Capital spending is expected to be about $320 million in 2026, and pension contributions approximately $55 million.
- The separation-related restructuring program has total expected pre-tax charges of $90 million and should finish in 2026.
- Capital return: a $2 billion buyback authorization approved in the fourth quarter of 2025, with the ASR as its first step.
- Financing plans include a new 364-day revolving credit facility in the second quarter 2026. Management points investors to Operating EBITDA as its segment profit measure.
What the latest 10-Q says
A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended September 30, 2026, filed November 3, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The quarter in brief
DuPont reported third-quarter net sales of $1.9 billion, up 4 percent, with both segments growing and manufacturing productivity improving profitability. Cash generation was much stronger than a year earlier, and the company kept returning cash through buybacks. Legacy PFAS settlements with New Jersey and North Carolina are now turning into cash payments, and the Middle East conflict is weighing on part of the water business.
How the business did
- Sales: Third-quarter net sales rose 4 percent from $1.8 billion, helped by a 5 percent rise in organic sales (growth excluding currency and acquisitions or divestitures) and offset by a 1 percent currency drag. Nine-month net sales were $5.4 billion, up 4 percent.
- Segments: Healthcare & Water Technologies had Operating EBITDA (the segment profit measure, roughly earnings before interest, taxes, depreciation and amortization, with adjustments) of $263 million, up 7 percent. Diversified Industrials had $242 million, up 11 percent. Management credited organic growth and manufacturing productivity. Cost of sales fell to 64 percent of net sales from 66 percent.
- Unusual items: The effective tax rate on continuing operations was 38.7 percent, against (12.1) percent a year earlier, which had included tax benefits tied to the Electronics separation. Interest expense was $40 million, down from $85 million. The Aramids sale closed April 1, 2026, and a 1-for-3 reverse stock split took effect June 24, 2026.
- Cash and capital return: Operating cash flow for nine months was $1,042 million, against $473 million a year earlier. Total debt was $3,094 million, down from $3,194 million at December 31, 2025. The company ran a $250 million accelerated buyback in August and declared a fourth-quarter dividend of $0.60 per share.
What management is watching
- Buybacks and restructuring: The company expects to repurchase $250 million of stock in the fourth quarter. Its 2026 DuPont Restructuring Program anticipates pre-tax charges and other cost savings of approximately $100 million to $150 million through 2028, with $60 million recorded so far.
- PFAS settlements: DuPont paid its first $71 million New Jersey payment on September 8, 2026. A North Carolina initial payment of $103 million ($36 million from DuPont) was made October 9, 2026. Qnity is contractually allocated 44 percent of these funding obligations.
- Outside pressures: Management is tracking Middle East disruptions, which held back Water Technologies, and the appeal process on refunds of tariffs the Supreme Court invalidated. The filing gives no numeric sales or earnings outlook. It points investors to organic sales and Operating EBITDA.
New or changed risks
- Middle East conflict named: The updated supply chain risk factor cites military conflicts such as those in the Middle East as a source of volatile energy markets, raw material shortages or higher costs, and constrained shipping routes.
- Liquidity access: The risk factor warns that a long or severe disruption could hurt the company's ability to meet customer commitments and to access the liquidity markets, reducing operating profit or cash flow.
- Limits on offsets: Price increases, productivity gains and cost cuts may not fully cover higher energy and raw material costs. The company says there is no guarantee that cost actions, delayed capital spending or reductions in force would significantly cushion the impact.
- Impairments: Results could be hit by factors not yet determined, including potential impairments of goodwill and other assets.
Follow DD in Kortex
The Kortex app shows DD's price, options chain and IV rank, and answers your questions from live market data and SEC filings.
Free to download.
Learn the strategies
More stock briefs
For education only, not financial advice. Options involve risk and are not suitable for every investor.